{
    "clinical_study": {
        "@rank": "63610", 
        "arm_group": [
            {
                "arm_group_label": "Sitagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Drug: sitagliptin sitagliptin 100mg tablet by mouth , once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "Vildagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Drug: vildagliptin saxagliptin 50mg tablet by mouth , twice daily for 12 weeks"
            }, 
            {
                "arm_group_label": "Saxagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Drug: saxagliptin saxagliptin 5mg tablet by mouth , once daily for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to explore the differences in efficacy and safety of\n      sitagliptin,vildagliptin and saxagliptin and to find which one is more better in treating\n      type 2 diabetes mellitus."
        }, 
        "brief_title": "Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin", 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  signed the informed consent\n\n          -  diagnosed with T2DM\n\n          -  women of childbearing potential were required to have a negative urine; pregnancy\n             test,and agreed to use adequate contraception throughout the; study and for up to 4\n             weeks after completion\n\n          -  glycosylated hemoglobin ranged in 7.0-9.0%\n\n        Exclusion Criteria:\n\n          -  patients in pregnancy or lactation period\n\n          -  ever received any kind of oral Hypoglycemic drug in recent 3 months\n\n          -  patients were currently receiving treatment with a cytochrome P450 3A4 inducer or\n             depressor,a systemic corticosteroid,or a human immunodeficiency virus anti-viral\n             medication\n\n          -  gastrointestinal surgery that could affect drug absorption\n\n          -  patients with haemoglobinopathy or rapidly progressing renal disease, or autoimmune\n             skin disorder\n\n          -  a recent history of alcohol or drug abuse within  the  past  12 months\n\n          -  any contraindication listed in the package inserts of the study drugs\n\n          -  a history of acute or chronic Pancreatitis or currently\n\n          -  type 1 diabetes; a history of diabetic ketoacidosis or hyperosmolar nonketonic coma\n\n          -  New York Heart Association class III or IV congestive heart failure; left ventricular\n             ejection fraction \u2264 40%; a major cardiovascular event within the past 6 months\n\n          -  significant abnormal liver function, defined as aspartate aminotransferase or alanine\n             aminotransferase > 2 times the upper limit of normal or total bilirubin >34 \u00b5mol/L (>\n             2 mg/dL); or a history of positive serologic evidence of infectious liver disease\n\n          -  clinical signs or symptoms of active  liver  disease  and/or  significant  abnormal\n             liver function\n\n          -  patients  with  any  clinically  significant abnormality  identified  on  physical\n             examination,  electrocardiogram (ECG),  or  laboratory  tests  that,  in  the\n             judgment  of  the investigator,  would  compromise  the  patients' safety  or\n             successful  participation  in  the  clinical  study\n\n          -  fasting plasma glucose level > 13.3mmol/l\n\n          -  creatinine clearance rate \u2264 90ml/min"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703637", 
            "org_study_id": "qfsnfm-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sitagliptin", 
                "description": "before breakfast\uff1aa tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy\nbefore dinner\uff1aa tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Januvia"
            }, 
            {
                "arm_group_label": "Vildagliptin", 
                "description": "before breakfast\uff1aa tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy\nbefore dinner\uff1aa tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy", 
                "intervention_name": "Vildagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Galvus"
            }, 
            {
                "arm_group_label": "Saxagliptin", 
                "description": "before breakfast\uff1aa tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy\nbefore dinner\uff1aa tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy", 
                "intervention_name": "Saxagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Onglyza"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vildagliptin", 
                "Sitagliptin", 
                "Saxagliptin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sitagliptin", 
            "Vildagliptin", 
            "Saxagliptin", 
            "Diabetes Mellitus, Type 2"
        ], 
        "lastchanged_date": "November 7, 2013", 
        "location": [
            {
                "contact": {
                    "email": "lpf9669@163.com", 
                    "last_name": "Pengfei Li"
                }, 
                "facility": {
                    "address": {
                        "city": "Dezhou", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "253000"
                    }, 
                    "name": "YuCheng people's hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "liaolin@medmail.com.cn", 
                    "last_name": "Lin Liao, MD", 
                    "phone": "8615168888260"
                }, 
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "250012"
                    }, 
                    "name": "Qianfoshan Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zhaoshunjiang@sohu.com", 
                    "last_name": "Zhaoshun Jiang"
                }, 
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "250010"
                    }, 
                    "name": "The jinan military region general hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "shuguangpang@163.com", 
                    "last_name": "Shuguang Pang"
                }, 
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "250010"
                    }, 
                    "name": "Jinan central hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fxl1936@163.com", 
                    "last_name": "Xiling Fu"
                }, 
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "250010"
                    }, 
                    "name": "Hospital of SINOTRUK"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "123raoxiaopang@163.com", 
                    "last_name": "Xiaopang Rao"
                }, 
                "facility": {
                    "address": {
                        "city": "Qingdao", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "266100"
                    }, 
                    "name": "People's Hospital of Qingdao Chengyang"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ling Dai", 
                    "phone": "+86 13853388549"
                }, 
                "facility": {
                    "address": {
                        "city": "Zibo", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "255000"
                    }, 
                    "name": "Zibo eighth people's hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "19xiaodong@163.com", 
                    "last_name": "Xiaodong Zhao"
                }, 
                "facility": {
                    "address": {
                        "city": "Zibo", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "255000"
                    }, 
                    "name": "Zibo central hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Randomized, Double-Blind Comparative Study of Efficacy\uff0cTolerance and Safety Between Sitagliptin ,Vildagliptin and Saxagliptin After 12-week Monotherapy in Drug-naive Adult Patients With Type 2 Diabetes Mellitus", 
        "other_outcome": [
            {
                "description": "We will choose 6 mutation types of CYP3A4 common in Chinese,and make blood medicinal concentration assay of participants with these gene types,and then analyse the association between different gene types and the change of glucose level or HbA1c or rate of adverse event.", 
                "measure": "gene polymorphism study", 
                "safety_issue": "No", 
                "time_frame": "baseline and week 12"
            }, 
            {
                "measure": "change from baseline in content of NOS", 
                "safety_issue": "No", 
                "time_frame": "baseline and week 12"
            }
        ], 
        "overall_contact": {
            "email": "liaolin@medmail.com.cn", 
            "last_name": "Lin Liao, MD", 
            "phone": "8615168888260"
        }, 
        "overall_official": {
            "affiliation": "Qianfoshan Hospital", 
            "last_name": "Lin Liao, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline reflects the Week 12 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin", 
            "measure": "Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 12", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703637"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Qianfoshan Hospital", 
            "investigator_full_name": "Lin Liao", 
            "investigator_title": "chief of endocrinology department at Qianfoshan Hospital", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "measure": "Change From Baseline in 2-hour Postprandial Glucose at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Change From Baseline in Fasting Insulin at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "measure": "Change From Baseline in Fasting Glucagon at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Change From Baseline in 2-hour Postprandial Insulin at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Change From Baseline in 2-hour Postprandial Glucagon at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Change From Baseline in 2-hour Postprandial Glucagon-like Peptide-1 (GLP-1) at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Change From Baseline in Body Weight at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "description": "fasting plasma lipid parameters including total cholesterol(TC), triglyceride(TG) and Low density lipoprotein(LDL)", 
                "measure": "Change From Baseline in Fasting Plasma Lipids at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "The Proportion of Patients Achieving A1C < 7% and Achieving A1C<6.5% at Week12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }
        ], 
        "source": "Qianfoshan Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lin Liao", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}